India, Sept. 10 -- AstraZeneca India, a leading global biopharmaceutical company, has announced the official launch of Eculizumab concentrate solution for infusion (300 mg,10 mg/ml) in India. This follows the Central Drugs Standard Control Organisation (CDSCO) approval received in January 2025 for the import, sale, and distribution of the product.

With this development, Eculizumab is now the first anti-complement therapy authorised in India for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) in both adults and children.

BothaHUSandPNHare ultra-rare, life-threatening disorders caused by chronic, uncontrolled activation of the complement system, leading to severe complications in bl...